vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and Fatpipe Inc (FATN). Click either name above to swap in a different company.
Fatpipe Inc is the larger business by last-quarter revenue ($4.1M vs $2.5M, roughly 1.6× Bolt Biotherapeutics, Inc.). Fatpipe Inc runs the higher net margin — 7.6% vs -265.2%, a 272.8% gap on every dollar of revenue.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
BOLT vs FATN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $4.1M |
| Net Profit | $-6.6M | $310.7K |
| Gross Margin | — | 87.7% |
| Operating Margin | -283.4% | 9.8% |
| Net Margin | -265.2% | 7.6% |
| Revenue YoY | — | 3.2% |
| Net Profit YoY | 58.4% | 816.0% |
| EPS (diluted) | $-9.38 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $4.1M | ||
| Q3 25 | $2.2M | $4.0M | ||
| Q2 25 | $1.8M | $3.9M | ||
| Q1 25 | $1.2M | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $5.3M | — |
| Q4 25 | $-6.6M | $310.7K | ||
| Q3 25 | $-7.1M | $-43.4K | ||
| Q2 25 | $-8.6M | $741.2K | ||
| Q1 25 | $-11.0M | — | ||
| Q4 24 | $-15.9M | — | ||
| Q3 24 | $-15.2M | — | ||
| Q2 24 | $-21.2M | — | ||
| Q1 24 | $-10.8M | — |
| Q4 25 | — | 87.7% | ||
| Q3 25 | — | 92.1% | ||
| Q2 25 | — | 94.2% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -283.4% | 9.8% | ||
| Q3 25 | -355.1% | -0.0% | ||
| Q2 25 | -510.5% | 25.5% | ||
| Q1 25 | -991.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1441.1% | — | ||
| Q2 24 | -1772.3% | — | ||
| Q1 24 | -324.1% | — |
| Q4 25 | -265.2% | 7.6% | ||
| Q3 25 | -329.4% | -1.1% | ||
| Q2 25 | -474.6% | 18.8% | ||
| Q1 25 | -903.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1330.1% | — | ||
| Q2 24 | -1662.4% | — | ||
| Q1 24 | -205.0% | — |
| Q4 25 | $-9.38 | $0.02 | ||
| Q3 25 | $-3.72 | $0.00 | ||
| Q2 25 | $-4.46 | $0.05 | ||
| Q1 25 | $-0.29 | — | ||
| Q4 24 | $-13.73 | — | ||
| Q3 24 | $-7.93 | — | ||
| Q2 24 | $-11.12 | — | ||
| Q1 24 | $-0.28 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | — |
| Total DebtLower is stronger | — | $4.6M |
| Stockholders' EquityBook value | $26.5M | $21.2M |
| Total Assets | $56.7M | $32.4M |
| Debt / EquityLower = less leverage | — | 0.22× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | — | ||
| Q3 25 | $31.9M | — | ||
| Q2 25 | $34.8M | — | ||
| Q1 25 | $38.8M | — | ||
| Q4 24 | $47.3M | — | ||
| Q3 24 | $53.8M | — | ||
| Q2 24 | $73.7M | — | ||
| Q1 24 | $91.3M | — |
| Q4 25 | — | $4.6M | ||
| Q3 25 | — | $4.8M | ||
| Q2 25 | — | $4.9M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $26.5M | $21.2M | ||
| Q3 25 | $32.1M | $21.0M | ||
| Q2 25 | $38.8M | $20.4M | ||
| Q1 25 | $46.8M | — | ||
| Q4 24 | $57.2M | — | ||
| Q3 24 | $72.0M | — | ||
| Q2 24 | $85.9M | — | ||
| Q1 24 | $104.2M | — |
| Q4 25 | $56.7M | $32.4M | ||
| Q3 25 | $65.1M | $32.2M | ||
| Q2 25 | $75.5M | $32.0M | ||
| Q1 25 | $85.9M | — | ||
| Q4 24 | $99.6M | — | ||
| Q3 24 | $109.3M | — | ||
| Q2 24 | $124.2M | — | ||
| Q1 24 | $142.9M | — |
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $240.9K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 0.78× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $240.9K | ||
| Q3 25 | $-9.7M | $399.8K | ||
| Q2 25 | $-9.6M | $-508.6K | ||
| Q1 25 | $-13.4M | — | ||
| Q4 24 | $-14.4M | — | ||
| Q3 24 | $-14.0M | — | ||
| Q2 24 | $-16.1M | — | ||
| Q1 24 | $-16.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-551.1K | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-14.0M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -14.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -1227.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.6% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | 0.78× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.69× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BOLT
Segment breakdown not available.
FATN
| Products | $2.6M | 63% |
| Other | $1.5M | 37% |
